Span Divergent reports Rs 7.59 crore subsidiary deficit

Span Divergent Limited said Biospan Contamination Control Solution Pvt. Ltd. had liabilities exceeding assets by Rs 7.59 crore at September 30, 2026, alongside accumulated losses of Rs 7.69 crore. Span Divergent prepared the subsidiary’s results on a going-concern basis, with management expecting product introductions to help restore profitability and positive net worth.

What did Span Divergent disclose about Biospan Contamination?

Span Divergent disclosed that Biospan Contamination’s total liabilities exceeded its total assets by Rs 7.59 crore at September 30, 2026. This deficit represents negative net worth, while the subsidiary’s accumulated losses reached Rs 7.69 crore through the same date.

The disclosure appears in the notes to Span Divergent’s consolidated unaudited results for the quarter and half year ended September 30, 2026, approved by the board on November 5, 2026. The filing does not provide a separate balance sheet, revenue figure, cash balance, borrowings figure or asset-liability composition for Biospan Contamination.

Span Divergent nevertheless prepared Biospan Contamination’s financial results on a going-concern basis. Management attributed the losses to temporary factors and said it believes the subsidiary can establish profitable operations, although the filing does not quantify a profit target or a date for achieving it.

How does Biospan Contamination compare with other subsidiaries?

Biospan Contamination’s Rs 7.69 crore accumulated losses were lower than the Rs 14.95 crore accumulated losses disclosed for Aranya Consulting and Biotech LLP at March 31, 2026. However, only Biospan Contamination’s note states the amount by which liabilities exceeded assets, at Rs 7.59 crore on September 30, 2026.

Aranya recorded a further Rs 1.37 lakh loss in the current year up to September 30, 2026, according to the filing. Its board approved a revival plan from a non-operational state after identifying potential new opportunities, and its assets were reclassified as property, plant and equipment, or PPE.

Biospan Scientific LLP is another separately disclosed entity, with accumulated losses of Rs 1.57 crore at March 31, 2019 that had substantially eroded its net worth. Span Divergent provided Rs 1.83 crore for impairment of its investment in Biospan Scientific during 2018-19 as an exceptional item, whereas the current filing discloses no comparable impairment amount for Biospan Contamination.

What is management’s plan for Biospan Contamination?

Management said appropriate product introductions should enable Biospan Contamination to generate adequate revenue, establish profitable operations and turn its negative net worth positive in the short-term horizon. This is management’s stated expectation rather than a disclosed sales forecast, funding commitment or product-launch schedule.

The filing does not identify the products, their expected launch dates, customers, revenue contribution or capital required for Biospan Contamination’s plan. It also does not say whether Span Divergent will provide additional funding to address the Rs 7.59 crore deficit at September 30, 2026.

The approach differs from the disclosure for Biospan Scientific, where management said it was exploring a revival either independently or through business tie-ups following losses reported at March 31, 2019. For Aranya, Span Divergent cited potential new opportunities and a board-approved operational revival plan after its Rs 14.95 crore accumulated losses at March 31, 2026.

What do Span Divergent’s consolidated finances show?

Span Divergent reported consolidated total assets of Rs 30.7659 crore at September 30, 2026, compared with Rs 28.9024 crore at March 31, 2026. Over the same period, total liabilities rose to Rs 22.8655 crore from Rs 19.0753 crore, while total equity including non-controlling interest declined to Rs 7.9004 crore from Rs 9.8271 crore.

The consolidated figures are not a substitute for Biospan Contamination’s standalone financial position because the filing gives no subsidiary balance sheet. They show that current borrowings increased by Rs 3.5257 crore between March 31 and September 30, 2026, while cash and cash equivalents fell by Rs 5.6332 crore to Rs 84.36 lakh.

For the six months ended September 30, 2026, Span Divergent reported net cash outflow from operating activities of Rs 7.2666 crore and net cash outflow from investing activities of Rs 1.5934 crore. Financing activities generated Rs 3.2268 crore, including Rs 3.5257 crore of proceeds from borrowings, but cash and cash equivalents still declined from Rs 6.4768 crore at March 31, 2026.

How does the preferential issue relate to the subsidiary?

Span Divergent raised Rs 5.7936 crore through a preferential issue allotted on March 28, 2026, and said the proceeds allocated to stated objects had been fully utilised by the quarter ended September 30, 2026. The company reported no deviation or variation from the purposes disclosed in the offer documents.

Of the total, Rs 5 crore was allocated to raw cashew nut inventory, Rs 50 lakh to restart and ramp-up costs, and Rs 29.36 lakh to selective refurbishment for productivity and quality. The filing does not state that any preferential-issue proceeds were allocated to Biospan Contamination’s product introductions or to reducing its Rs 7.59 crore negative net worth.

The preferential issue therefore describes funding for cashew-related operating requirements rather than a disclosed recapitalisation of Biospan Contamination. Future disclosures would need to identify any funding, product introduction, revenue or balance-sheet change specifically connected to management’s short-term restoration plan.

Conclusion

Biospan Contamination had accumulated losses of Rs 7.69 crore and liabilities exceeding assets by Rs 7.59 crore at September 30, 2026, making it a specifically identified financial-stress issue in Span Divergent’s results. The company has retained the going-concern basis, while group liabilities rose to Rs 22.8655 crore and consolidated cash fell to Rs 84.36 lakh.

The next point to watch is management’s plan to use appropriate product introductions to generate adequate revenue and restore positive net worth in the short-term horizon. Span Divergent has not disclosed a product timetable, revenue target, separate Biospan Contamination balance sheet or funding commitment, leaving subsequent financial results to show progress.